Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This change reflects revised expectations for the company's long-term potential. The ...
54m
Tom Norton
Tom Norton is Newsweek's Fact Check reporter, based in London. His focus is reporting on misinformation and misleading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback